Vir Biotechnology Inc VIR

$9.58 -0.38 (-3.82%)

Valuation

Market cap
1,705,859,000
Revenue TTM
$68,560,000
Net income TTM
$-437,990,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-638.84%
Debt to equity
0.00

Trading

Volume
6,781,618
Avg volume
2,354,470
Day's range
$9.57 – $10.04
Shares out
171,271,000
Stochastic %K
5%
Beta
1.70
Analysts
Strong Buy
Price target
$22.55

Price

Company profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A a...

Show more

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 906 4324
Website
https://www.vir.bio
Address
1800 Owens Street, Suite 900, San Francisco, United States

Latest news

Stocktwits

H143capital Nov 16, 10:37 PM
What’s the strongest argument against owning BridgeBio today? $OMER $BA $VIR $INSM $ABVX I remain bullish, but my latest article also examines competition, pipeline setbacks and debt—alongside the upside I see. Read “Surviving Was Just the Beginning” and tell me where you disagree. Long BBIO. https://h143capital.substack.com/p/bridgebio-pharma-surviving-was-just
0 replies
Letthegamesbegin Nov 16, 6:08 PM
$VIR Douchebag svrewed us all.
0 replies
Dunnieboy1 Nov 16, 6:02 PM
$VIR poor old Brent Sabatini only got 50,000 for $0. Might get a job there the terms are very generous, these guys are accountants not scientists.
1 replies
Dunnieboy1 Nov 16, 5:49 PM
$VIR Sawaf Aziz Chief Financial Officer has just picked up 225,000 shares for $0, as they say ’nice work if you can get it’.
0 replies
Techdamentals Nov 16, 3:31 PM
$VIR fell 17.82% to $9.96 on Friday, November 13, 2026. It fell after pricing 15 million new shares at $10 each. Moves like that make people ask one thing: where does the price sit against what the business is worth? The Techdamentals IV Calculator shows a fair value range built from the company's own reported numbers. See the range for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v/VIR?ref=st
0 replies
soksobay Nov 16, 3:08 PM 0 replies
Merlintrader Nov 16, 10:31 AM
$VIR | NEWS – Nov 13 Vir raises 150 million dollars after ECLIPSE 1 Phase 3 success. Offering priced at 10.00 dollars per share for 15 million shares, days after ECLIPSE 1 in hepatitis delta met its primary endpoint. Source: Vir press release (Business Wire), Nov 13, 2026; 424B5, Nov 12, 2026. Not investment advice. Details and primary sources in our $VIR stock hub: https://www.merlintrader.com/vir-biotechnology-stock-hub/
0 replies
animegirlinvestor Nov 16, 6:32 AM
$VIR buy the dip
0 replies